

VT

PATENTES

BIOTECNOLOGÍA SANITARIA

Degeneración macular
Diabetes
Sistema nervioso
Sistema inmune

16



asebio

NIPO:
073-15-032-8

**Vigilancia
Tecnológica**
2º trimestre 2017

Este Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge del trabajo conjunto entre la Oficina Española de Patentes y Marcas (OEPM) y ASEBIO como miembro de la Plataforma Tecnológica Española de Mercados Biotecnológicos, y se encuadra dentro de una de las actividades de colaboración que la OEPM viene llevando a cabo con las referidas Plataformas para hacer llegar a las empresas, investigadores, y organizaciones que las integran una selección de las patentes más recientemente publicadas en determinados sectores tecnológicos.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecen una información puntual, esquemática y de rápida lectura sobre una selección de las últimas patentes biotecnológicas publicadas en el

mundo relativas a cuatro líneas de investigación concretas: Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular. A través del número de publicación de cada patente, un enlace permite consultar el documento completo e incluso poder disponer de una traducción de la descripción realizada con la herramienta Patent translate.


También incluyen noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios. Si se desea recibir este Boletín periódicamente basta con cumplimentar el correspondiente [formulario de suscripción](#).

Se puede acceder al listado de solicitudes de patentes analizadas pulsando sobre las imágenes que aparecen a continuación.


Contenido




DEGENERACIÓN
MACULAR



DIABETES



SISTEMA NERVIOSO



SISTEMA INMUNE

Degeneración Macular

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017085550	OLIX PHARMACEUTICALS INC [KR]	Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3
WO2017083791	ICONIC THERAPEUTICS INC [US]	Methods and compositions for treating disorders associated with pathological neovascularization
WO2017066529	MASSACHUSETTS EYE AND EAR INFIRMARY [US]	High-dose statins for age-related macular degeneration
WO2017062750	THE TRUSTEES OF THE UNIV OF PENNSYLVANIA [US]	Compositions and methods useful in treating Stargardt's disease and other ocular disorders
WO2017026694	RES COOP FOUND OF YEUNGNAM UNIV [KR]	Pharmaceutical composition for preventing or treating ocular diseases, containing CD9 antibody as active ingredient
WO2017079443	SANOBI BIOTECHNOLOGY [FR]; REGENERON PHARMA [US]	Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
WO2017075212	GENENTECH INC [US]; F HOFFMANN-LA ROCHE AG [CH]	Anti-HtrA1 antibodies and methods of use thereof
WO2017075259	GENENTECH INC [US]; F HOFFMANN-LA ROCHE AG [CH]	Anti-factor D antibody formulations
WO2017075173	GENENTECH INC [US]; F HOFFMANN-LA ROCHE AG [CH]	Anti-Factor D antibodies and conjugates
WO2017072515	SYNCONA MAN LLP [GB]	Gene therapy
WO2017062649	ALEXION PHARMA INC [US]; WANG YI [US]; ROHRER BARBEL [US]	A method for treating age-related macular degeneration in a patient
WO2017042239	SYLENTIS SAU [ES]	siRNA and their use in methods and compositions for inhibiting the expression of the CHI3L1 gene
WO2017042238	SYLENTIS SAU [ES]	siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene

Diabetes

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017091737	MOLECULAR DEFENSES CORP [US]	Pharmaceutical formulations
WO2017086627	UBIPROTEIN CORP [KR]	A method for extending half-life of a protein
WO2017086703	RETI MARK CO LTD [KR]; SEOUL NAT UNIV BUNDANG HOSPITAL [KR]	Biomarker for diagnosing age-related macular degeneration or diabetic retinopathy and method for diagnosis using same
WO2017083925	GARVAN INST MED RES [AU]	Compounds and methods for treating metabolic disorders
WO2017079505	RES INST AT NATIONWIDE CHILDREN'S HOSPITAL [US]	RNAse7 for treatment of bacterial infection
WO2017078439	DAEGU GYEONGBUK INST OF SCIENCE AND TECH [KR]	Pharmaceutical composition for treating diabetes, comprising pancreatic islet cells and elastin-like artificial extracellular matrix
WO2017075583	UNIV NEW YORK STATE RES FOUND [US]; CALIFORNIA INST BIOMEDICAL RES [US]	Oxyntomodulin analogs and methods of making and using same
WO2017074798	MERCK SHARP & DOHME [US]; PALANI ANANDAN [US]; NARGUND RAVI [US]; CARRINGTON PAUL E [US]; SAWYER TOMI [US]; DENG QIAOLIN [US]; PESSI ANTONELLO [IT]; BIANCHI ELISABETTA [IT]; ORVIETO FEDERICA [IT]	Long-acting co-agonists of the glucagon and GLP-1 receptors
WO2017073786	KIKKOMAN CORP [JP]	Glucose dehydrogenase having modified electron transfer properties, and glucose measurement method
WO2017075505	UNIV TUFTS [US]; TUFTS MEDICAL CENTER [US]	Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
WO2017074117	YUHAN CORP [KR]	Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same
WO2017074123	YUHAN CORP [KR]	Dual function proteins and pharmaceutical composition comprising same

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017073740	UNIV SAITAMA MEDICAL [JP]	Method for producing pancreatic endocrine cells, and transdifferentiation agent
WO2017070617	UNIV CASE WESTERN RESERVE [US]	Diol-modified insulin analogues containing a glucose-regulated conformational switch
WO2017070114	JIA WEI [US]	Diabetes-related biomarkers and treatment of diabetes-related conditions
WO2017062334	MERCK SHARP & DOHME [US]; AMBRX INC [US]; GARBACCIO ROBERT M [US]; CARRINGTON PAUL E [US]; SEGHEZZI WOLFGANG [US]; ERMAKOV GRIGORI [US]; BIANCHI ELISABETTA [IT]; ORVIETO FEDERICA [IT]; KNUDSEN NICK [US]; MANIBUSAN ANTHONY [US]; GATELY DENNIS [US]	Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
WO2017061750	COLLEGE OF MEDICINE POCHON CHA UNIV INDUSTRY-ACADEMIC COOP FOUND [KR]; REPUBLIC OF KOREA(MANAGEMENT : RURAL DEV ADMINISTRATION) [KR]	Pharmaceutical composition for prevention or treatment of diabetic foot ulcer
WO2017059205	IONIS PHARMACEUTICALS INC [US]	Combination therapy
WO2017053622	MIRAGEN THERAPEUTICS INC [US]	miR-19 modulators and uses thereof
WO2017052321	HANMI PHARM IND CO LTD [KR]	Protein conjugate comprising multiple bioactive polypeptides and immunoglobulin Fc regions
WO2017048741	ANTHROGENESIS CORP [US]	Treatment of diabetic peripheral neuropathy using placental cells
WO2017047800	UNIV TOHOKU [JP]	Nucleic acid molecule
WO2017044847	SYMBIOCELLTECH LLC [US]	Neo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith
WO2017039267	HANMI PHARM IND CO LTD [KR]	Novel insulin analogs and use thereof
WO2017041001	THE CALIFORNIA INST FOR BIOMEDICAL RES [US]	Insulin immunoglobulin fusion proteins
WO2017039345	PUSAN NAT UNIV INDUSTRY-UNIV COOP FOUND [KR]	One-time-use amperometric detection method for simultaneously measuring hemoglobin and glycated hemoglobin
WO2017035472	UNIV CALIFORNIA [US]	Chiral conversion of amyloid proteins associated with diseases

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017031985	BGI SHENZHEN [CN]	Intestinal bacteria <i>Butyribacterintestini</i> and application thereof
WO2017026462	KYOTO PREFECTURAL PUBLIC UNIV CORP [JP]	Method for preparing brown adipocyte
WO2017024198	THE TRUSTEES OF THE UNIV OF PENNSYLVANIA [US]	GLP-1 and use thereof in compositions for treating metabolic diseases
WO2017024076	UNIV CALIFORNIA [US]	Cell transplantation device
WO2017020786	GUANGZHOU ZHIYI PHARMACEUTICAL INC [CN]	Application of bacteroides fragilis in treating and/or preventing obesity or diabetes
WO2017019957	NGM BIOPHARMACEUTICALS INC [US]	Binding proteins and methods of use thereof
WO2017018641	POSCO [KR]; POSTECH ACADEMY-INDUSTRY FOUND [KR]	Insulin receptor aptamer and pharmaceutical composition containing same aptamer against insulin receptor and pharmaceutical composition containing the same
WO2017015760	SOC DE COMMERCIALISATION DES PRODUITS DE LA RECH APPLIQUEE SOCPIA SCIENCES SANTE ET HUMAINES S E C [CA]	A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
WO2017015497	INDIANA UNIV RES & TECH CORP [US]; UNIVERSITÉ LIBRE DE BRUXELLES [BE]	Cell-free methylated and unmethylated dna in diseases resulting from abnormalities in blood glucose levels
WO2017093465	SANOFI SA [FR]	FGF21 variants
WO2017089612	DOUBLEGOOD AB [SE]	Food supplement and composition for treating the metabolic syndrome
WO2017079768	GENENTECH INC [US]; F HOFFMANN-LA ROCHE AG [CH]	Methods of screening for multispecific antibodies
WO2017081112	ECOLE NAT VETERINAIRE [FR]; CHU NANTES [FR]; UNIV DE NANTES [FR]; INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) [FR]	Si-HPMC-encapsulated insulin-producing cells for the treatment of type 1 diabetes
WO2017077120	BRAUN ALEXANDER [DE]; ELSNER MARTIN [DE]; GRIEBLER CHRISTIAN [DE]	Diagnosis of diabetes
WO2017077016	MEDIZINISCHE UNIVERSITÄT INNSBRUCK [AT]; KING'S COLLEGE LONDON [GB]	MicroRNA-122 in metabolic diseases
WO2017074715	LILLY CO ELI [US]	Glucagon receptor agonists
WO2017066204	REGENERON PHARMA [US]	Antigen-binding proteins that activate the leptin receptor

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017074714	LILLY CO ELI [US]	Glucagon receptor agonists
WO2017063657	PHLOGO APS [DK]	IL1RA-derived peptide antagonist
WO2017055872	UCL BUSINESS PLC [GB]	Diabetes gene therapy
WO2017052455	ANARA AB [SE]	Amylase fragments for blood glucose control
WO2017060179	F HOFFMANN-LA ROCHE AG [CH]; HOFFMANN-LA ROCHE INC [US]	Therapeutic peptides
WO2017034956	LILLY CO ELI [US]	Rapid-acting insulin compositions
WO2017042814	YEDA RES & DEV [IL]	Use of perforin positive immature dendritic cells in disease treatment
WO2017050955	INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) [FR]; UNIVERSITÉ PARIS DESCARTES [FR]; ASSIST PUBLIQUE-HÔPITAUX DE PARIS (APHP) [FR]; FOND IMAGINE [FR]; CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]; CNAM - CONSERVATOIRE NAT DES ARTS ET MÉTIERS [FR]	Agents capable of inhibiting the binding between leptin and VEGF165
WO2017042751	UNIV DE LOS ANDES [CL]	In vitro method for identifying a pregnancy related disease
WO2017046335	INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) [FR]; UNIVERSITÉ PARIS DESCARTES [FR]; CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]	T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
WO2017042347	UNIVERSITÉ CATHOLIQUE DE LOUVAIN [BE]; WAGENINGEN UNIV [NL]	Use of pasteurized <i>Akkermansia</i> for treating metabolic disorders
WO2017042242	HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) [DE]	Novel IGFR-like receptor and uses thereof
WO2017042238	SYLENTIS SAU [ES]	siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene
WO2017032798	NOVO NORDISK AS [DK]	Novel insulin derivatives and the medical uses hereof
WO2017032795	NOVO NORDISK AS [DK]	Novel insulin derivatives and the medical uses hereof
WO2017032815	HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) [DE]	Biomarkers for cardiometabolic diseases

Sistema Nervioso

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017087868	UNIV LELAND STANFORD JUNIOR [US]	B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components
WO2017079834	THE UNIV OF BRITISH COLUMBIA [CA]	Epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2017083700	THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA LAS VE [US]	Ligand-guided phagocytosis based therapy for treatment of Alzheimer's Disease and other neurodegenerative diseases
WO2017079832	THE UNIV OF BRITISH COLUMBIA [CA]	C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2017079835	THE UNIV OF BRITISH COLUMBIA [CA]	Amyloid beta epitopes and antibodies thereto
WO2017079831	THE UNIV OF BRITISH COLUMBIA [CA]	N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2017079833	THE UNIV OF BRITISH COLUMBIA [CA]	Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
WO2017078175	JAPAN ROYAL JELLY CO LTD [JP]; UNIV TOHOKU [JP]	Enhancer of anti-dementia activity of royal jelly
WO2017073798	TEIJIN PHARMA LTD [JP]	Pharmaceutical composition intended to be administered to nasal mucosa
WO2017070731	INNATE IMMUNOTHERAPEUTICS LTD [AU]	Compositions and methods for the treatment of Alzheimer's disease
WO2017065541	DONGGUK UNIV INDUSTRY-ACADEMIC COOP FOUND [KR]; UNIV-INDUSTRY COOP GROUP OF KYUNG HEE UNIV [KR]	Composition for prevention or treatment of degenerative brain diseases
WO2017062983	THE CHILDREN'S HOSPITAL OF PHILADELPHIA [US]	Compositions and methods for treating Huntington's disease and related disorders

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017061818	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR]; INDUSTRY-UNIVERSITY COOP FOUND HANYANG [KR]; SNU R&DB FOUND [KR]	Mutant genes as diagnostic markers for amyotrophic lateral sclerosis and diagnostic method using same
WO2017057523	KEIO UNIV [JP]	Astrocyte-like cells and method for preparing same
WO2017058895	QUEST DIAGNOSTICS INVEST LLC [US]	Amyloid beta detection by mass spectrometry
WO2017053753	SANGAMO BIOSCIENCES INC [US]	Htt repressors and uses thereof
WO2017053838	OKLAHOMA MED RES FOUND [US]; AXTELL ROBERT C [US]; STEINMAN LAWRENCE [US]; UNIV LELAND STANFORD JUNIOR [US]	Biomarkers for assessing subjects with multiple sclerosis
WO2017043466	EISAI R&D MAN CO LTD [JP]	Anti-EphA4 antibody
WO2017044807	UNIV COLUMBIA [US]	Reduction of ER-MAM-localized APP-C99 and methods of treating Alzheimer's disease
WO2017040813	UNIV MASSACHUSETTS [US]	Detection of gene loci with CRISPR arrayed repeats and/or polychromatic single guide ribonucleic acids
WO2017041037	UNIV COLUMBIA [US]	Disruption of the interaction between amyloid beta peptide and dietary lipids
WO2017040594	CEDARS-SINAI MEDICAL CENTER [US]	Novel blood cell biomarker for late onset Alzheimer's disease
WO2017039525	LOBSOR PHARMACEUTICALS AB [SE]	Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-O-methyltransferase inhibitor
WO2017039251	CHA BIOTECH CO LTD [KR]	Enhanced postnatal adherent cell, and use for same
WO2017037324	SERVICIO ANDALUZ DE SALUD [ES]; FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD [ES]; UNIV SEVILLA [ES]	Biomarkers for amyotrophic lateral sclerosis (ALS)
WO2017034031	NAT CENTER OF NEUROLOGY AND PSYCHIATRY [JP]; UNIV TOKYO [JP]; SCHOOL CORP AZABU VETERINARY MEDICINE EDUCATIONAL INST [JP]; JUNTENDO EDUCATIONAL FOUND [JP]	Autoimmune disease diagnosis method, autoimmune disease diagnosis biomarker, and autoimmune disease preventing or treating agent
WO2017035472	UNIV CALIFORNIA [US]	Chiral conversion of amyloid proteins associated with diseases

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017034244	IUCF-HYU (INDUSTRY-UNIVERSITY COOP FOUND HANYANG UNIVERSITY) [KR]	Peptide having effect of preventing or treating central nervous system diseases and pharmaceutical composition for preventing and treating central nervous system diseases, containing same as active ingredient
WO2017030292	UNIV SEOUL NAT R & DB FOUND [KR]; KOREA RES INST OF BIOSCIENCE AND BIOTECHNOLOGY [KR]	Prevention and treatment of neurodegenerative diseases through autophagy activity mediated by ligand or arginylated BiP binding to p62 ZZ domain
WO2017028708	SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE [CN]	Recombinant lipoprotein modified by monosialotetrahexosylganglioside and application thereof
WO2017027691	UNIV NEW YORK [US]	Antibody-based molecules selective for the {p}Ser404 Epitope of Tau and their uses in the diagnosis and treatment of tauopathy
WO2017027685	UNIV NEW YORK [US]	Antibody-based molecules specific for the truncated Asp421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
WO2017027280	THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE [US]	Chemical reprogramming to generate neuronal cells
ES2600386	GRIFOLS WORLDWIDE OPERATIONS LTD [IE]	Método de diagnóstico in vitro de la enfermedad de Alzheimer basado en el nivel redox de la albumina en el líquido cefalorraquídeo
WO2017019862	TEVA PHARMA [IL]; TEVA PHARMA [US]; LINDEN GALINA [IL]; COHEN RAKEFET [IL]; LICHT DANIT [IL]	Combination formulation of laquinimod and glatiramer acetate with amino acids
WO2017015198	COHERUS BIOSCIENCES INC [US]	Stable aqueous formulations of natalizumab
WO2017008638	CHANGCHUN BCHT BIOTECHNOLOGY CO [CN]; UNIV JILIN [CN]	Chimeric norovirus P particle and preparation and use thereof
WO2017087677	ALLERGAN INC [US]	Botulinum toxin administration for treatment of neurogenic detrusor overactivity associated urinary incontinence
WO2017077329	IMP INNOVATIONS LTD [GB]; FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA [ES]	Nucleic acids, peptides and methods
WO2017075432	ALECTOR LLC [US]	Anti-Siglec-9 antibodies and methods of use thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017085214	GEROA DIAGNOSTICS S L [ES]	Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease, or in the diagnosis of Parkinson's disease
WO2017075535	OXEIA BIOPHARMACEUTICALS INC [US]	Methods of treating neurodegenerative conditions
WO2017066657	AQUINNAH PHARMACEUTICALS INC [US]; UNIV BOSTON [US]; LARSEN GLENN R [US]; WOLOZIN BENJAMIN [US]; VANDERWEYDE TARA [US]; APICCO DANIEL J [US]	Nucleic acid based TIA-1 inhibitors
WO2017062682	GENENTECH INC [US]; F HOFFMAN LA-ROCHE AG [CH]	Method for treating multiple sclerosis
WO2017077066	FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E V [DE]	Composition comprising a biocompatible and biodegradable polymer, nanocarriers and a drug and methods of making and using the same
WO2017062672	ALECTOR LLC [US]	Anti-TREM2 antibodies and methods of use thereof
WO2017051135	NEURONAX [FR]	Cyclic polypeptides, method for obtaining said polypeptides and the therapeutic use thereof
WO2017072090	GLAXOSMITHKLINE IP DEV LTD [GB]	Combination therapy
WO2017059122	THE US SECRETARY DEPT OF HEALTH AND HUMAN [US] US HEALTH [US]	Methods of treating and preventing amyotrophic lateral sclerosis
WO2017064308	PROQR THERAPEUTICS II B V [NL]	Antisense oligonucleotides for use in treating Alzheimer's disease
WO2017060510	INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) [FR]; UNIVERSITÉ PARIS-SUD [FR]; COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES [FR]; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6) [FR]; ASSIST PUBLIQUE-HÔPITAUX DE PARIS (APHP) [FR]	Methods and pharmaceutical compositions for the treatment of Alzheimer's disease
WO2017055542	F HOFFMANN-LA ROCHE AG [CH]; HOFFMANN-LA ROCHE INC [US]	Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
WO2017055540	F HOFFMANN-LA ROCHE AG [CH]; HOFFMANN-LA ROCHE INC [US]	Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use
WO2017055487	MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT [DE]	A method for diagnosing a disease by detection of circRNA in bodily fluids

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017044862	ABBVIE INC [US]; ABBVIE DEUTSCHLAND [DE]	Methods for treating relapsing forms of multiple sclerosis
WO2017042814	YEDA RES & DEV [IL]	Use of perforin positive immature dendritic cells in disease treatment
WO2017071889	CENTRE NAT RECH SCIENT [FR]; INST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM) [FR]; COLLEGE DE FRANCE [FR]; UNIV PARIS CURIE [FR]	Homeoproteins for use in the treatment of neurodegenerative disorders
WO2017042577	BV BIOMED LTD [GB]	Novel therapy
WO2017050803	UNIVERSITÄT DUISBURG-ESSEN [DE]	Agents inhibiting Kallikrein-8 for use in the prevention or treatment of Alzheimer's disease
WO2017046267	TOPOSNOMOS LTD [DE]	Pharmaceutical agents for use in the treatment of amyotrophic lateral sclerosis (ALS), and diagnostic methods
WO2017037057	HUMMINGBIRD DIAGNOSTICS GMBH [DE]	Novel miRNA biomarkers and use thereof
EP3121277	IMMUNAS PHARMA INC [JP]; NAT CENTER FOR GERIATRICS AND GERONTOLOGY [JP]	Antibody capable of binding specifically to Ab-oligomer, and use thereof
WO2017013252	ECOLE POLYTECHNIQUE FED DE LAUSANNE (EPFL) [CH]	Bicistronic AAV vector for RNA interference in ALS
WO2017016982	F HOFFMANN-LA ROCHE AG [CH]; HOFFMANN-LA ROCHE INC [US]; ROCHE NIMBLEGEN INC [US]	BACE1 inhibitor peptides
WO2017005734	UCB BIOPHARMA SPRL [BE]	Tau-binding antibodies
WO2017030563	BIOGEN MA INC [US]	PEGylation method

Sistema Inmune

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017104779	CHUGAI PHARMACEUTICAL CO LTD [JP]	Anti-C5 antibodies and methods of use
WO2017087735	MILLENNIUM PHARM INC [US]	Method for treating Crohn's disease
WO2017087838	GEORGE MASON UNIV [US]	Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta
WO2017082562	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR]	Stem cell with suppressed SOCS and improved immunosuppressive ability and use thereof
WO2017079430	BIOINCEPT LLC [US]	Peptides and methods of treating endometriosis using the same
WO2017079639	MAYO FOUNDATION [US]	Methods and materials for treating autoimmune conditions
WO2017075522	UNIV TUFTS [US]; TUFTS MEDICAL CENTER [US]	GLP-2 polypeptides with improved proteolytic stability, and methods of preparing and using same
WO2017070076	ALBERT EINSTEIN COLLEGE MEDICINE INC [US]	Therapeutic TNFR-1B targets and uses thereof
WO2017067480	INST OF BIOTECHNOLOGY ACAD OF MILITARY MEDICAL SCIENCES PLA [CN]	Human-derived anti-human multi-subtype interferon α antibody and application thereof
WO2017066136	EUREKA THERAPEUTICS INC [US]	Antibody agents specific for human CD19 and uses thereof
WO2017063196	SHENZHEN INST OF ADV TECH CAS [CN]; THE TRUSTEES OF THE UNIV OF PENNSYLVANIA [US]	C-Rel-specific siRNA and application thereof for treating autoimmune psoriasis
WO2017062685	BIONIZ LLC [US]	Modulating gamma - c -cytokine activity
WO2017062253	CIRCLE33 LLC [US]	Antibodies with improved stability to intestinal digestion
WO2017062035	ABT HOLDING CO [US]; KING'S COLLEGE LONDON [GB]; DEANS ROBERT J [US]; READING JAMES [GB]; STUBBLEFIELD SAMANTHA [US]; TREE TIMOTHY [GB]	Methods for enhancing proliferation of T regulatory cells

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017061655	UNIV ULSAN FOUND FOR IND COOP [KR]	Composition for diagnosing refractory inflammatory bowel disease in pediatric patients, comprising single nucleotide polymorphism marker in IL10RA gene
WO2017061125	NAT INST OF BIOMEDICAL INNOVATION HEALTH AND NUTRITION [JP]	Therapy, diagnosis, and screening using CARD14
WO2017059225	CELGENE CORP [US]; CELGENE ALPINE INVEST COMPANY II LLC	TLR modulators and methods of use
WO2017058752	DARTMOUTH COLLEGE [US]	Chimeric antigen receptor anti-inflammatory cells and methods of use
WO2017058828	CHILDREN'S HOSPITAL LOS ANGELES [US]	Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
WO2017048097	KANGSTEM BIOTECH CO LTD [KR]	Composition for preventing or treating inflammatory diseases, containing, as active ingredient, stem cells overexpressing SOD3
WO2017044855	UNIV RUTGERS [US]; BARNES BETSY J [US]	Cell penetrating peptides that inhibit IRF5 nuclear localization
WO2017038986	MOCHIDA PHARM CO LTD [JP]	Method for producing recombinant protein
WO2017044665	IMRAN MIR [US]; KORUPOLU RADHIKA [US]; TO ELAINE [US]; HARRIS JOEL [US]; HASHIM MIR [US]	PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2017035017	THE CHILDREN'S HOSPITAL OF PHILADELPHIA [US]	Methods of treating autoimmune conditions in patients with genetic variations in DcR3 or in a DcR3 network gene
WO2017035010	THE CHILDREN'S HOSPITAL OF PHILADELPHIA [US]	Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
WO2017025954	IMMUNARRAY LTD [IL]	Methods for determining the risk of a systemic lupus erythematosus (SLE) patient to develop neuropsychiatric syndromes
WO2017022962	THE CATHOLIC UNIV OF KOREA INDUSTRY-ACADEMIC COOP FOUND [KR]	Composition for preventing or treating immune disease, comprising RIPK inhibitor as active ingredient

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017019756	LANKANEU INST FOR MEDICAL RES [US]	Methods and compositions for the treatment of immunomodulatory diseases and disorders
WO2017018288	NAT UNIV CORP EHIME UNIV [JP]	Peptide fragment for treating autoimmune diseases
WO2017010807	MEDICINAL BIOCONVERGENCE RES CENTER [KR]	Novel polypeptide having chemokine activity
WO2017087811	MASSACHUSETTS INST TECHNOLOGY [US]; RIPKA JULIANE FLORENTINE [DE]	Engineered bacteroides outer membrane vesicles
WO2017093947	NOVARTIS AG [CH]	Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2017089794	4D PHARMA RES LTD [GB]	Compositions comprising bacterial strains
WO2017085172	ABLYNX NV [BE]	Improved serum albumin binders
WO2017081320	ABLYNX NV [BE]	Improved TNF binders
WO2017064564	GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD [GB]	Therapeutic regimens for treating psoriatic arthritis with an anti-CCL20 antibody
WO2017081218	UNIVERSITÄTSKLINIKUM REGENSBURG [DE]	Anti-human IL-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of IL-3, and their use in a method to detect human IL-3
WO2017070569	OREGON HEALTH & SCIENCE UNIV [US]; THE US GOV AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS [US]	Compounds that bind macrophage migration inhibitory factor
WO2017077062	LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN [DE]; MAASTRICHT UNIV [NL]; ACAD ZIEKENHUIS MAASTRICHT [NL]	A peptide derived from human neutrophil peptide 1
WO2017072494	UNIV OXFORD INNOVATION LTD [GB]	Peptide and biomarker associated with inflammatory disorders, and uses thereof
WO2017076924	TIGENIX S A U [ES]	Mesenchymal stem cell-derived exosomes and their uses
WO2017076804	GLAXOSMITHKLINE IP DEV LTD [GB]	Treatment paradigm
WO2017062672	ALECTOR LLC [US]	Anti-TREM2 antibodies and methods of use thereof
WO2017072183	UCB BIOPHARMA SPRL [BE]	Methods of treatment using anti-IL-17A/F antibodies
EP3159007	EISAI R&D MAN CO LTD [JP]	Pharmaceutical composition for treating rheumatoid arthritis

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2017044811	ANDRIEN BRUCE [US]; HUNTER JEFFREY [US]; MALANSON HUNTER [US]	Recombinant glycosylated eculizumab and eculizumab variants
WO2017049024	CEPHALON INC [US]	Antibodies that specifically bind to TL1A
WO2017060289	MORPHOSYS AG [DE]; GALAPAGOS NV [BE]	Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
WO2017048901	BOEHRINGER INGELHEIM INT [DE]; BOECHER WULF OTTO [DE]; GALLER ANNETTE BETTINA [DE]; LALOVIC BOJAN [US]; PADULA STEVEN JOHN [US]; SCHOLL PAUL [US]; VISVANATHAN SUDHA [US]	Methods of treating inflammatory diseases
WO2017050976	INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) [FR]; UNIVERSITÉ D'AIX MARSEILLE [FR]; GFRS (GROUPE FRANCOPHONE DE RECH SUR LA SCLÉRODERMIE SYSTÉMIQUE) [FR]	EphB2 polypeptides and uses thereof for the diagnosis and treatment of lupus
EP3141907	SYSMEX CORP [JP]	Reagent kit for detecting lupus anticoagulant and method for determining presence or absence of lupus anticoagulant
WO2017050833	GLAXOSMITHKLINE INTELLECTUAL PROPERTY MAN LTD [GB]	Dosing regimen of combination of anti-CD20 and anti-BLyS antibodies
WO2017040566	BOEHRINGER INGELHEIM INT [DE]	Use of anti-CD40 antibodies for treatment of lupus nephritis
WO2017035426	PROCTER & GAMBLE [US]; ALIMENTARY HEALTH LTD [IE]	<i>Bifidobacterium longum</i>
WO2017037150	CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]; UREKA SARL [FR]	Quaternary assemblies of water-soluble non-peptide helical foldamers, their use and production thereof
WO2017032739	INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) [FR]; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6) [FR]; INST NAT DE LA RECH AGRONOMIQUE (INRA) [FR]; CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]; ASSIST PUBLIQUE-HÔPITAUX DE PARIS (APHP) [FR]	Pharmaceutical compositions for preventing or treating inflammatory bowel diseases
WO2017021450	ENGMAB AG [CH]	Monoclonal antibodies against BCMA
EP3167892	INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) [FR]; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6) [FR]; INST NAT DE LA RECH AGRONOMIQUE (INRA) [FR]; CENTRE NAT DE LA RECH SCIENT -CNRS- [FR]	Methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases

Noticias

Plan Estratégico 2017-2020 de la OEPM en materia de Propiedad Industrial

El Plan Estratégico 2017-2020 en materia de Propiedad Industrial (PI) es una iniciativa de la Oficina Española de Patentes y Marcas, Organismo Autónomo de la Administración del Estado, que pretende constituir la Propiedad Industrial como herramienta y factor clave en la toma de decisiones cotidianas de las empresas y de los emprendedores y crear a su vez una verdadera cultura basada en el conocimiento de la PI.

La OEPM apuesta porque la Propiedad Industrial se convierta en un factor clave en las decisiones que se toman cotidianamente en el ámbito empresarial y para ello, el conocimiento en materia de PI debe partir desde la formación más temprana de nuestros estudiantes. Para ello, la OEPM necesita el consorcio con socios estratégicos que apuesten por la misma vocación innovadora con visión de futuro.



Así pues mediante las 27 medidas del Plan se pretende impulsar la diferenciación, especialización y mayor rendimiento del sistema productivo español para mejorar así la posición competitiva de nuestras empresas en los mercados globales mediante el uso estratégico de los instrumentos de protección de la Propiedad Industrial (PI). En particular las pequeñas y medianas empresas (PYME) y los emprendedores, que son no sólo la fuerza motriz que impulsa nuestra economía, sino también los principales contribuyentes a la creación de puestos de trabajo.

Este Plan se enmarca dentro de la Estrategia Europa 2020 para una economía sostenible que plantea reformas hacia un modelo renovado de crecimiento basado en una economía inteligente, sostenible e integradora que disfrute de altos niveles de empleo, de productividad y de cohesión social y su objetivo son las empresas. Se trata de un proyecto que aúna esfuerzos y coordina actuaciones en los diferentes ámbitos que conciernen a la PI: industria, comercio, educación, difusión, formación, investigación, justicia y acción exterior.

[Más información](#)

La OEPM promueve el uso de la información de patentes entre las universidades españolas.

Dentro del marco de colaboración establecido por el Convenio suscrito el pasado mes de diciembre entre la OEPM y las universidades españolas, el 31 de mayo, la OEPM ha comenzado una campaña divulgativa dirigida a los investigadores de todas las universidades del país. El objeto de la misma es trasladarles la importancia de utilizar las patentes como documentación científico-técnica a lo largo de un proyecto de investigación, fundamentalmente en los momentos iniciales, para así evitar investigaciones redundantes, llegar a resultados patentables y que estos sean más fácilmente transferibles a la industria. Las búsquedas de patentes cobran aún una mayor relevancia tras la reciente entrada en vigor de la nueva Ley de Patentes que establece el procedimiento con examen como único procedimiento de concesión. En estas charlas también se comentan los aspectos más relevantes de la nueva Ley de Patentes incidiendo especialmente en los que afectan al entorno universitario.

Esta campaña empezó con una charla en la Universidad Politécnica de Madrid, dirigida a investigadores de las distintas universidades madrileñas y se repetirá a lo largo de los próximos meses en distintas universidades del país. Ya se han realizado jornadas durante el mes de junio en las universidades de Salamanca, Castellón, Politécnica de Valencia, Murcia, León, Islas Baleares y Politécnica de Cartagena.

Se han previsto ulteriores actividades dirigidas al personal investigador universitario para dar continuidad a esta iniciativa, cuyo objetivo no es otro que integrar plenamente la Propiedad Industrial y el uso de la información de patentes, en particular, en los proyectos de investigación y transferencia de tecnología de las universidades españolas.

Nueva Alerta Tecnológica sobre "TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES"

La OEPM publica una nueva Alerta Tecnológica sobre "Tecnología para la monitorización y control de la diabetes", que se incorpora a las ya existentes relacionadas con Ciencias de la Vida. Se ha realizado a petición del Instituto de Automática e Informática Industrial de la Universidad Politécnica de Valencia, como resultado de las distintas actividades que la OEPM está llevando a cabo con las Universidades españolas y en virtud del Convenio de colaboración suscrito con ellas el pasado mes de diciembre.

Esta nueva Alerta sobre "Tecnología para la monitorización y control de la diabetes" recoge las publicaciones diarias de patentes relativas a sistemas inalámbricos de detección de glucosa en sangre, biosensores de glucosa, sistemas automatizados de infusión de insulina, etc.

La finalidad de las Alertas Tecnológicas es proporcionar información actualizada diariamente sobre las patentes publicadas en el mundo en relación a un tema técnico concreto.

Así son ya diecinueve las Alertas disponibles en la web de la OEPM en distintos sectores técnicos

